Sawai Outlook Improves But Japanese Generics Continue To Suffer Under NHI Price Cuts
Prospect Of Regulatory Reform For Japanese Generics Remains Uncertain
Executive Summary
Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.
You may also be interested in...
Sunsho Acquisition Finally Paying Off For Towa
After several lackluster quarters, Towa’s acquisition of Sunsho Pharmaceutical is finally paying off for the Japanese generics firm.
Down But Not Out: Nichi-Iko Hives Off Sagent, Exits North America
Seven years after it paid almost three quarters of a billion dollars for US-based Sagent, troubled Nichi-Iko is offloading the struggling business.
Japan’s Drug Distribution Crisis: Pharma Urges Govt To Reform Pricing System
The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.